Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC)

D. Baumunk(Klinikum Magdeburg), Steffen Weikert(St. Hedwig-Krankenhaus), Jan Ebbing(Charité - Universitätsmedizin Berlin), Martin Schostak(Aturo), Hannes Cash(Royal Free London NHS Foundation Trust), Uta Reichelt(Charité - Universitätsmedizin Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin), Jannis Hildebrandt(Charité - Universitätsmedizin Berlin), Hans Krause(Charité - Universitätsmedizin Berlin)
World Journal of Urology
April 28, 2012
10.1007/s00345-012-0874-5
Cited by 39

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218